Owen B. Wallace

Jnana Therapeutics (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

22h-index2.6kcitations70works12.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Estrogen and related hormone effects(11), Genetics and Neurodevelopmental Disorders(10), HIV/AIDS drug development and treatment(8), Computational Drug Discovery Methods(6), Muscle Physiology and Disorders(6)

Publications70 total

Mining the CRBN target space redefines rules for molecular glue–induced neosubstrate recognition
Science·2025· 43 cited
Mining the CRBN Target Space Redefines Rules for Molecular Glue-induced Neosubstrate Recognition
2024· 17 citedOpen Access
POS1200 MRT-6160, A VAV1-DIRECTED MOLECULAR GLUE DEGRADER, REDUCES JOINT INFLAMMATION, CYTOKINE PRODUCTION, AND AUTOANTIBODY LEVELS IN A COLLAGEN-INDUCED ARTHRITIS DISEASE MODEL
Annals of the Rheumatic Diseases·2024
Tu1727 MRT-6160, A VAV1-DIRECTED MOLECULAR GLUE DEGRADER, INHIBITS DISEASE PROGRESSION IN A T-CELL TRANSFER MEDIATED MURINE COLITIS MODEL CONCOMITANT WITH REDUCED CALPROTECTIN EXPRESSION
Gastroenterology·2024· 1 cited
Abstract 3294: The GSPT1 molecular glue degrader MRT-2359 is active against prostate cancer
Cancer Research·2024· 6 cited
P164 MRT-6160, a VAV1-directed molecular glue degrader, inhibits disease progression and inflammation in a T-cell transfer model of Colitis
Journal of Crohn s and Colitis·2024· 5 citedOpen Access
Spatially coordinated heterochromatinization of long synaptic genes in fragile X syndrome
Cell·2023· 26 citedOpen Access
Abstract ND10: Discovery of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for MYC-driven cancers
Cancer Research·2023· 4 cited
Abstract 3449: Development of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for the treatment of lung cancers with MYC-induced translational addiction
Cancer Research·2023· 14 cited
Fragile X Syndrome Patient–Derived Neurons Developing in the Mouse Brain Show FMR1-Dependent Phenotypes
Biological Psychiatry·2022· 2 cited
Abstract 3929: Identification of MRT-2359 a potent, selective and orally bioavailable GSPT1-directed molecular glue degrader (MGD) for the treatment of cancers with Myc-induced translational addiction
Cancer Research·2022· 23 cited
Fragile X syndrome patient-derived neurons developing in the mouse brain show <i>FMR1</i> -dependent phenotypes
2021Open Access
APPLICATION OF NEXT GENERATION TECHNOLOGIES
Neuromuscular Disorders·2021
Spatially coordinated heterochromatinization of distal short tandem repeats in fragile X syndrome
2021· 5 citedOpen Access
Induction of Fetal Hemoglobin By FTX6058, a Novel Small Molecule Development Candidate
Blood·2020
<i>In Vivo</i> Characterization of Ftx-6058, a Novel Small Molecular Fetal Hemoglobin Inducer for Sickle Cell Disease
Blood·2020· 4 cited
<i>In Vitro</i> Characterization of FTX6058, a Novel Small Molecule Fetal Hemoglobin Inducer for Sickle Cell Disease
Blood·2020· 1 cited
Human-mouse chimeric Fragile X syndrome model reveals FMR1-dependent neuronal phenotypes
Research Square (Research Square)·2020Open Access
FSHD / OPMD / MYOTONIC DYSTROPHY
Neuromuscular Disorders·2020
p38α Regulates Expression of DUX4 in a Model of Facioscapulohumeral Muscular Dystrophy
Journal of Pharmacology and Experimental Therapeutics·2020· 42 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Milind Deshpande(8), Débora Bonenfant(8), Wade Blair(7), Nicholas A. Meanwell(7), Yi-Fei Gong(6), Pei‐Yong Shi(6), Pin-fang Lin(6), Jeffrey A. Dodge(6), Andrew G. Geiser(6), Henry U. Bryant(6), Arnaud Osmont(6), Angela Cacace(6), Hao Wu(6), Hwei-Gene Heidi Wang(5), Brett A. Robinson(5), Bernhard Fasching(5), Luis Alejandro Rojas(5), Filip Jankú(5), Haiquan Fang(4), Timothy Spicer(4)